Please login to the form below

Not currently logged in
Email:
Password:

drug abuse

This page shows the latest drug abuse news and features for those working in and with pharma, biotech and healthcare.

Sage gets final US clearance for postpartum depression drug Zulresso

Sage gets final US clearance for postpartum depression drug Zulresso

Controlled drug needs special REMS monitoring. Sage Therapeutics has gained clearance from the US Drug Enforcement Administration (DEA) to make its postpartum depression treatment Zulresso available to the first patients. ... The drug gained approval

Latest news

  • FDA panel backs J&J’s new-class antidepressant FDA panel backs J&J’s new-class antidepressant

    have potential for abuse, like its parent drug ketamine. ... It has listed the drug as a potential $1bn product, although Evaluate analysts are a bit more conservative, predicting annual revenues of $490m by 2020.

  • AcelRX’s potent opioid tablets set to win FDA backing for pain relief AcelRX’s potent opioid tablets set to win FDA backing for pain relief

    This time the application included a Risk Evaluation Mitigation Strategy (REMS), stating that the drug must be administered by a trained healthcare professional to avoid substance abuse and accidental exposures. ... This measure has helped to swing the

  • FDA panel backs Indivior’s drug to fight opioid addiction FDA panel backs Indivior’s drug to fight opioid addiction

    Indivior is on course to bring a new drug to market to tackle painkiller addiction in the US, offsetting the risks to its business from generic competition. ... An FDA advisory committee backed approval of Indivior’s RBP-6000 drug by a vote of eighteen

  • FDA panel backs Pfizer and Teva abuse-resistant painkillers FDA panel backs Pfizer and Teva abuse-resistant painkillers

    However, it would not back a label claim that the product could prevent abuse of the drug via the oral route, but said it could discourage abuse by people seeking to ... Last month the same panel also rejected an abuse-deterrent claim for KemPharm's

  • FDA gives green light for opioid addiction implant FDA gives green light for opioid addiction implant

    He added: “Opioid abuse and addiction have taken a devastating toll on American families. ... Nora Volkow, director of the National Institute on Drug Abuse, said: “Scientific evidence suggests that maintenance treatment with these medications in the

More from news
Approximately 3 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    9.5. Savant HWP / National Institute on Drug Abuse. Development grant. ... 18-MC (18-methoxycoronaridine) as a treatment for drug addiction, obesity and compulsive behaviour.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Confidential contracting – the road to flexible pricing

    A post on  drug pricing by Joseph Jimenez, then CEO of Novartis, attracted a lot of attention in 2016. ... The use of growth hormones (GH) among adolescents is concerning, particularly if the patient is an athlete or has a bodybuilder relative who could

  • Innovative pricing and contracting options

    The use of growth hormones (GH) among adolescents is concerning, particularly if the patient is an athlete or has a bodybuilder relative who could abuse the access to the drug. ... Easypod is an electromechanical injection device that delivers the GH

  • "Legal highs" ruling leaves illegal labs laughing

    We have also pitched for agents designed to treat opioid overdose and alcohol abuse.  . ... Drug abuse is a massive medical and social problem in the UK, and it has been compounded by the availability of new psychoactive agents virtually everywhere.

  • How digital content is helping physicians curb the opioid abuse epidemic

    using their state’s Prescription Drug Monitoring Program (PDMP) database before prescribing opioids to a patient. ... After all, having physicians more frequently access these state PMDPs at the point of prescription can go a long way to preventing

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics